Roche/Zeneca Nolvadex agreement
Executive Summary
Roche would copromote Zeneca's Nolvadex (tamoxifen) for breast cancer prevention under non-binding tentative agreement announced Aug. 28. The new indication for tamoxifen will be reviewed by FDA's Oncologic Drugs Advisory Committee Sept. 2
Roche would copromote Zeneca's Nolvadex (tamoxifen) for breast cancer prevention under non-binding tentative agreement announced Aug. 28. The new indication for tamoxifen will be reviewed by FDA's Oncologic Drugs Advisory Committee Sept. 2. |